Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Chemistry

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44393   clinical trials with a EudraCT protocol, of which   7405   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,699 result(s) found for: Chemistry. Displaying page 75 of 85.
    «« First « Previous 71  72  73  74  75  76  77  78  79  Next» Last»»
    EudraCT Number: 2020-001244-26 Sponsor Protocol Number: COV-2-SOLNATIDE-20 Start Date*: 2020-04-11
    Sponsor Name:Department of Clinical Pharmacology, Medical University of Vienna, Vienna Austria
    Full Title: COVID-19: Efficacy of solnatide to treat pulmonary permeability oedema in SARS-Cov-2 positive patients with moderate-to-severe ARDS - a pilot-trial.
    Medical condition: Pulmonary permeability oedema in SARS-Cov-2 positive patients with moderate-to-severe ARDS
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003083 ARDS LLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037423 Pulmonary oedema PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000685-15 Sponsor Protocol Number: AXA1125-101 Start Date*: 2021-10-18
    Sponsor Name:Axcella Health, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability, and Efficacy of AXA1125 in Subjects With Non Cirrhotic, Non Alcoholic Steatohepatitis and Fi...
    Medical condition: Noncirrhotic, Nonalcoholic Steatohepatitis and Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    24.1 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-003210-13 Sponsor Protocol Number: LYT-100-2020-02 Start Date*: 2020-10-27
    Sponsor Name:PureTech LYT 100, Inc.
    Full Title: A Phase 2 Randomized, Double-blind, Placebo-controlled Trial and Open Label Extension to Evaluate the Safety and Efficacy of Deupirfenidone (LYT- 100) in Post-acute COVID-19 Respiratory Disease
    Medical condition: COVID-19 respiratory disease
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084270 SARS-CoV-2 acute respiratory disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003315-60 Sponsor Protocol Number: A201 Start Date*: 2020-11-10
    Sponsor Name:Criceto IKM B.V.
    Full Title: A phase 1/2 study investigating the pharmacokinetics, safety and efficacy of a highly concentrated buccal formulation of apomorphine (APORON®) in subjects with Parkinson's Disease
    Medical condition: Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-004429-26 Sponsor Protocol Number: CMP0119 Start Date*: 2020-05-08
    Sponsor Name:PRZEDSIEBIORSTWO FARMACEUTYCZNE LEK-AM SPÓŁKA Z OGRANICZONA ODPOWIEDZIALNOSCIA
    Full Title: A multicentre, randomized, open-label, cross-over equivalence study to compare the pharmacodynamic properties, safety, and tolerability of a new combination dry powder of fluticasone propionate and...
    Medical condition: asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-002911-23 Sponsor Protocol Number: DS102A-08-CV2 Start Date*: 2020-10-12
    Sponsor Name:Afimmune
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Exploratory Phase IIa Study to Assess the Mechanism of Action and Safety of Orally Administered Epeleuton in Patients with Type 2 Diabetes and Diabet...
    Medical condition: Type 2 diabetes and diabetic complications
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    20.0 10014698 - Endocrine disorders 10012653 Diabetic complications HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-002641-42 Sponsor Protocol Number: C4591001 Start Date*: 2020-09-04
    Sponsor Name:BioNTech SE
    Full Title: A PHASE 1/2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COV...
    Medical condition: Protection against COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-000763-23 Sponsor Protocol Number: ANJ900D3501 Start Date*: 2021-12-28
    Sponsor Name:Anji Pharma (US) LLC
    Full Title: A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo- and Comparator-Controlled Study to Compare the Glycemic Effects, Safety, and Tolerability of Metformin Hydrochloride Delayed-Releas...
    Medical condition: Type 2 Diabetes Mellitus with varying renal function from normal up to CKD3B
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) PL (Completed) BG (Completed) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-001631-82 Sponsor Protocol Number: EDP2939-101 Start Date*: 2022-11-29
    Sponsor Name:Evelo Biosciences, Inc.
    Full Title: A Phase 1/2, randomised, placebo-controlled study of EDP2939 in healthy volunteers and participants with moderate plaque psoriasis.
    Medical condition: Moderate plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2016-001930-93 Sponsor Protocol Number: GC-627-04 Start Date*: 2017-01-13
    Sponsor Name:Generon (Shanghai) Corporation Ltd.
    Full Title: A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo Controlled Clinical Trial of F-627 in Women with Breast Cancer Receiving Myelotoxic Chemotherapy
    Medical condition: Women, between 18 and 75 years of age that have been diagnosed with Stage II-IV breast cancer in the adjuvant or metastatic setting and are scheduled to undergo chemotherapy. This is a profilaxis ...
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    19.0 10005329 - Blood and lymphatic system disorders 10016288 Febrile neutropenia PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2017-002026-20 Sponsor Protocol Number: CT7001-001 Start Date*: 2017-10-31
    Sponsor Name:Carrick Therapeutics
    Full Title: A Modular, Multipart, Multiarm, Open-label, Phase I/IIa Study to Evaluate the Safety and Tolerability of CT7001 Alone and in Combination with Anti-cancer Treatments in Patients with Advanced Malign...
    Medical condition: Module 1A: All solid malignancies Module 1B: Solid malignancies, potentially including TNBC, SCLC, CRPC, ovarian cancer patients, and other appropriate cancer indications. Module 1B-1 (TNBC):...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2020-003956-34 Sponsor Protocol Number: 73763989PAHPB2006 Start Date*: 2021-01-16
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2, Open-label, Single-arm, Multicenter Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of Treatment With JNJ-73763989, JNJ-56136379, Nucleos(t)ide Analogs, and Pegylate...
    Medical condition: Chronic Hepatitis B Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10008910 Chronic hepatitis B PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2018-002652-33 Sponsor Protocol Number: T-Haplo-for-SCD Start Date*: Information not available in EudraCT
    Sponsor Name:University Hospital of Regensburg
    Full Title: A phase 2 trial to assess haploidentical Alpha/ß T-depleted stem cell transplantation in patients with sickle cell disease with no available sibling donor
    Medical condition: Sickle Cell Disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003064-50 Sponsor Protocol Number: HLX10-004-NSCLC303 Start Date*: 2020-06-17
    Sponsor Name:Shanghai Henlius Biotech, Inc.
    Full Title: A Randomized, Double-Blind, Multicenter, Phase III Clinical Study of HLX10 (Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection) + Chemotherapy (Carboplatin-Nanoparticle Albumin-Bound (na...
    Medical condition: First-Line Therapy for Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-005406-54 Sponsor Protocol Number: M14TIL Start Date*: 2014-05-09
    Sponsor Name:Antoni van Leeuwenhoek ziekenhuis
    Full Title: Randomized phase III study comparing a non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor infiltrating lymphocytes and interleukin-2 to standard ipilimumab...
    Medical condition: Patients with unresectable and metastatic (stage IIIc and stage IV) melanoma will be randomized to either treatment arm A (ipilimumab) or treatment arm B (TIL) after metastasectomy and feasibility ...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-000060-22 Sponsor Protocol Number: 2020/0424/HP Start Date*: 2023-04-03
    Sponsor Name:CHU de Rouen
    Full Title: Comparison of a personalized maintenance therapy based on the evolution of anti-desmoglein antibodies as biomarkers of pemphigus subclinical activity, with the standard treatment (rituximab + corti...
    Medical condition: Pemphigus diseases (Pemphigus Vulgaris - PV and Pemphigus Foliaceus (PF).
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10067776 Ocular pemphigoid PT
    20.0 10040785 - Skin and subcutaneous tissue disorders 10034277 Pemphigoid PT
    21.1 10040785 - Skin and subcutaneous tissue disorders 10057052 Cicatricial pemphigoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-005027-16 Sponsor Protocol Number: NOA-18 Start Date*: 2020-09-16
    Sponsor Name:Heidelberg University Hospital Represented in law by its Commercial Managing Director
    Full Title: Improvement of functional Outcome for patients with newly diagnosed grade 2 or 3 glioma with co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 trial
    Medical condition: WHO grade 2 or 3 glioma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018338 Glioma PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030288 Oligodendroglioma malignant LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003931-27 Sponsor Protocol Number: GI2118 Start Date*: 2021-10-20
    Sponsor Name:Department of Oncology, Herlev & Gentofte Hospital
    Full Title: Nivolumab, ipilimumab and radiation in combination with influenza vaccine in patients with pancreatic cancer.
    Medical condition: Metastatic pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10033604 Pancreatic cancer LLT
    21.1 100000004864 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-000245-12 Sponsor Protocol Number: Repha_1436 Start Date*: 2020-01-20
    Sponsor Name:Repha GmbH
    Full Title: Controlled clinical trial to evaluate the efficacy and safety of MYRRHINIL-INTEST® versus placebo in patients with diarrhea-dominant irritable bowel syndrome (IBS-D) and patients with mixed-type ir...
    Medical condition: A confirmed diagnosis of irritable bowel syndrome (IBS-D or IBS-M) by a specialist in gastroenterology and/or internal medicine and/or general medicine
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10023002 Irritable bowel LLT
    26.0 10017947 - Gastrointestinal disorders 10060845 Diarrhea predominant irritable bowel syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-002327-11 Sponsor Protocol Number: 213403 Start Date*: 2021-02-05
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A RANDOMIZED, PHASE 2, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY OF DOSTARLIMAB PLUS CHEMOTHERAPY VERSUS PEMBROLIZUMAB PLUS CHEMOTHERAPY IN METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
    Medical condition: Metastatic non-squamous non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10079440 Non-squamous non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 71  72  73  74  75  76  77  78  79  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Apr 05 07:32:45 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA